Recombinant mouse TNF_alpha (E.coli_derived)
- Known as:
- Recombinant mouse TNF_alpha (E.coli_derived)
- Catalog number:
- CT304
- Product Quantity:
- 10 µg
- Category:
- -
- Supplier:
- U-CyTech
- Gene target:
- Recombinant mouse TNF_alpha (.coli_derived)
Related products to: Recombinant mouse TNF_alpha (E.coli_derived)
Related articles to: Recombinant mouse TNF_alpha (E.coli_derived)
- Over the last two years, inflammatory dermatology has undergone a transition from morphology-based classification toward pathway-driven immune endotyping. Atopic dermatitis, psoriatic disease, and hidradenitis suppurativa have emerged as paradigmatic models of this transition, illustrating how epithelial dysfunction, involving autoinflammation and adaptive immunity, may lead to systemic inflammatory crosstalks, connecting cutaneous and musculoskeletal manifestations. Recent studies have refined the understanding of progressive immune maturation in atopic dermatitis, while psoriasis and juvenile psoriatic arthritis support skin-to-joint inflammatory models involving IL-23/IL-17 signaling. Hidradenitis suppurativa is increasingly recognized as a systemic autoinflammatory disease within a broader neutrophilic inflammatory spectrum. Parallel therapeutic advances involving IL-17, IL-23, TNF, and JAK inhibition reinforced the translational importance of these discoveries and accelerated the development of precision dermatology strategies. - Source: PubMed
Publication date: 2026/07/28
Cattalini MarcoAmerio PaoloBertolla DavideRuperto NicolinoGualdi Giulio - Cutaneous vulvar Crohn's disease (VCD) is a rare, diagnostically challenging condition requiring a patient-specific treatment approach. Biologic agents are emerging as effective targeted immunotherapies, with established evidence to support the efficacy of tumor necrosis factor (TNF)-alpha inhibitors and growing evidence for interleukin (IL) inhibitors, namely ustekinumab and risankizumab. IL inhibitors have shown promise in the treatment of refractory VCD cases requiring more targeted immunosuppression or after prior TNF-alpha inhibitor failure. Three cases of VCD managed by varying biologic agents are presented, in which ustekinumab achieved remission of symptoms in the first and risankizumab achieved control in the third. This series highlights the importance of assessing disease location and extent, immunosuppression risks, concurrent conditions, and treatment history to inform biologic selection. - Source: PubMed
Publication date: 2026/07/28
Conlin Emily MElas Diane EBartolo-Costello Abigail AStockdale Colleen K - Functional esophageal disorders (FEDs) are disorders of gut-brain interaction frequently accompanied by chronic insomnia disorder (CID), but their cortical neuronal basis remains unclear. This study aimed to investigate spontaneous cortical activity in FEDs using resting-state functional magnetic resonance imaging with amplitude of low-frequency fluctuation (ALFF) analysis and to examine its associations with sleep disturbance and peripheral inflammation. - Source: PubMed
Publication date: 2026/07/06
Peng BeiZhong LikunHuang JinfuCui MengHuang DanOuyang YinfeiLiang XiaoliLi HaoqiangHuang XinghuaLin ZhimingLiang YuemingHuang ChunlingLiang YunxiaoDeng Demao - Xiaoer Fengreqing (XF), a traditional Chinese medicine, is included in pediatric COVID-19 guidelines, but its active components and mechanisms remain unclear. This study aimed to explore XF's bioactive constituents and potential effects against COVID-19-related encephalitis. - Source: PubMed
Publication date: 2026/07/15
Chen RuihanLi XuanxuanWang MengleiXiong YueyueXie PeifangLiu YanCui ZhanyuYe YiLi RunfengHon ChitinMa Qinhai - To compare the therapeutic effects of proprioceptive neuromuscular facilitation (PNF) versus traditional rehabilitation (electroacupuncture combined with infrared irradiation) on tendon-bone healing in a rat model of rotator cuff tear. - Source: PubMed
Publication date: 2026/07/06
Liang ZhiruChen WeihongKang JingyunTang BoHuang LeiLiu Peng